Table 1.
Patient characteristics
| Resected specimens | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tumour biopsies before neoadjuvant CTx | All | Without neoadjuvant CTx | After neoadjuvant CTx | ||||||
| Category | Value | n | % | n | % | n | % | n | % |
| Cases | Total | 143 | 100 | 617 | 100 | 291 | 100 | 326 | 100 |
| Age (years) | Median | 61.1 | 64.6 | 68.1 | 61.3 | ||||
| Range | 23.1–78.0 | 28.3–90.9 | 32.1–90.9 | 28.3–81.2 | |||||
| Follow‐up period (month) | Median | 69.6 | 57.9 | 58.8 | 56.7 | ||||
| 95% CI | 61.6–77.6 | 53.1–62.7 | 50.7–66.9 | 47.4–66.0 | |||||
| Overall survival (month) | Median | 48.1* | 44.6 | 85.0 | 32.4 | ||||
| 95% CI | 26.2–70.0 | 30.2–59.0 | 51.7–118.3 | 23.0–41.8 | |||||
| Sex | Male | 109 | 76.2 | 453 | 73.4 | 193 | 66.3 | 260 | 79.8 |
| Female | 34 | 23.8 | 164 | 26.6 | 98 | 33.7 | 66 | 20.2 | |
| Localisation | Proximal | 100 | 69.9 | 301 | 48.8 | 97 | 33.3 | 204 | 62.6 |
| Middle | 23 | 16.1 | 153 | 24.8 | 84 | 28.9 | 69 | 21.2 | |
| Distal | 14 | 9.8 | 131 | 21.2 | 92 | 31.6 | 39 | 12.0 | |
| Total/linitis | 6 | 4.2 | 28 | 4.5 | 14 | 4.8 | 14 | 4.3 | |
| N/A | 0 | 0 | 4 | <1 | 4 | 1.4 | 0 | 0 | |
| Laurén histological subtype | Intestinal | 72 | 50.3 | 347 | 56.2 | 155 | 53.3 | 192 | 58.9 |
| Non‐intestinal | 71 | 49.7 | 270 | 43.8 | 136 | 46.7 | 134 | 41.1 | |
| Tumour grade | G1/2 | 33 | 23.1 | 125 | 20.3 | 80 | 27.5 | 45 | 13.8 |
| G3/4 | 110 | 76.9 | 400 | 64.8 | 210 | 72.5 | 190 | 58.3 | |
| N/A | 0 | 0 | 92 | 14.9 | 1 | 0 | 91 | 27.9 | |
| cT | cT2 | 8 | 5.6 | 144 | 23.3 | 129 | 44.3 | 15 | 4.6 |
| cT3/cT4 | 131 | 91.6 | 471 | 76.3 | 161 | 55.3 | 310 | 95.1 | |
| N/A | 4 | 2.8 | 2 | <1 | 1 | <1 | 1 | <1 | |
| (y) pT† | (y) pT0 | 9 | 6.3 | 0 | 0 | 0 | 0 | 0 | 0 |
| (y) pT1 | 12 | 8.4 | 56 | 9.1 | 42 | 14.4 | 14 | 4.3 | |
| (y) pT2 | 20 | 14.0 | 79 | 12.8 | 47 | 16.2 | 32 | 9.8 | |
| (y) pT3 | 81 | 56.6 | 328 | 53.2 | 139 | 47.8 | 189 | 58.0 | |
| (y) pT4 | 19 | 13.3 | 154 | 25.0 | 63 | 21.6 | 91 | 27.9 | |
| N/A | 2 | 1.4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| (y) pN | Negative | 61 | 42.7 | 189 | 30.6 | 104 | 35.7 | 85 | 26.1 |
| Positive | 80 | 55.9 | 428 | 69.4 | 187 | 64.3 | 241 | 73.9 | |
| N/A | 2 | 1.4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Metastasis status | No | 97 | 67.8 | 534 | 86.5 | 272 | 93.5 | 262 | 80.4 |
| Yes | 44 | 30.8 | 83 | 13.5 | 19 | 6.50 | 64 | 19.6 | |
| N/A | 2 | 1.4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Resection status | R0 | 117 | 81.8 | 469 | 76.0 | 235 | 80.8 | 234 | 71.8 |
| R1 | 24 | 16.8 | 148 | 24.0 | 56 | 19.2 | 92 | 28.2 | |
| N/A | 2 | 1.4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Tumour regression status | TRG1 | 45 | 31.4 | 0 | |||||
| TRG2 | 34 | 23.8 | 154 | 47.2 | |||||
| TRG3‡ | 64 | 44.8 | 172 | 52.8 | |||||
| Response | Responder | 45 | 31.5 | 0 | 0 | ||||
| (TRG1) | |||||||||
| Non‐Responder | 98 | 68.5 | 326 | 100 | |||||
| (TRG2/3)‡ | |||||||||
| EBV status | Positive | 6§ | 4.2 | 24 | 3.9 | 8§ | 2.7 | 16 | 4.9 |
| Negative | 137 | 95.8 | 593 | 96.1 | 283 | 97.3 | 310 | 95.1 | |
| MSI status | MSS | 121 | 84.6 | 530 | 85.9 | 241 | 82.8 | 289 | 88.7 |
| MSI‐L | 7§ | 4.9 | 28 | 4.5 | 15§ | 5.2 | 13 | 4.0 | |
| MSI‐H | 15 | 10.5 | 59 | 9.6 | 35 | 12.0 | 24 | 7.4 | |
N/A, not available.
*
OS was defined as time between the date of operation and death by any cause. For two patients who were not operated; the date of start of CTx was used.
†
Classification according to 7th Edition UICC 2007.
‡
Two patients with tumour progression during CTx were not operated on; they were classified as TRG3 and a Non‐responder respectively.
§
One tumour biopsy and one resected tumour without neoadjuvant CTx were positive for both MSI‐L and EBV.